{"2411.14157": {"publish_time": "2024-11-20", "title": "DrugGen: Advancing Drug Discovery with Large Language Models and Reinforcement Learning Feedback", "paper_summary": "Traditional drug design faces significant challenges due to inherent chemical\nand biological complexities, often resulting in high failure rates in clinical\ntrials. Deep learning advancements, particularly generative models, offer\npotential solutions to these challenges. One promising algorithm is DrugGPT, a\ntransformer-based model, that generates small molecules for input protein\nsequences. Although promising, it generates both chemically valid and invalid\nstructures and does not incorporate the features of approved drugs, resulting\nin time-consuming and inefficient drug discovery. To address these issues, we\nintroduce DrugGen, an enhanced model based on the DrugGPT structure. DrugGen is\nfine-tuned on approved drug-target interactions and optimized with proximal\npolicy optimization. By giving reward feedback from protein-ligand binding\naffinity prediction using pre-trained transformers (PLAPT) and a customized\ninvalid structure assessor, DrugGen significantly improves performance.\nEvaluation across multiple targets demonstrated that DrugGen achieves 100%\nvalid structure generation compared to 95.5% with DrugGPT and produced\nmolecules with higher predicted binding affinities (7.22 [6.30-8.07]) compared\nto DrugGPT (5.81 [4.97-6.63]) while maintaining diversity and novelty. Docking\nsimulations further validate its ability to generate molecules targeting\nbinding sites effectively. For example, in the case of fatty acid-binding\nprotein 5 (FABP5), DrugGen generated molecules with superior docking scores\n(FABP5/11, -9.537 and FABP5/5, -8.399) compared to the reference molecule\n(Palmitic acid, -6.177). Beyond lead compound generation, DrugGen also shows\npotential for drug repositioning and creating novel pharmacophores for existing\ntargets. By producing high-quality small molecules, DrugGen provides a\nhigh-performance medium for advancing pharmaceutical research and drug\ndiscovery.", "paper_summary_zh": "\u50b3\u7d71\u85e5\u7269\u8a2d\u8a08\u56e0\u5176\u5316\u5b78\u548c\u751f\u7269\u8907\u96dc\u6027\u800c\u9762\u81e8\u91cd\u5927\u6311\u6230\uff0c\u9019\u901a\u5e38\u6703\u5c0e\u81f4\u81e8\u5e8a\u8a66\u9a57\u7684\u9ad8\u5931\u6557\u7387\u3002\u6df1\u5ea6\u5b78\u7fd2\u7684\u9032\u5c55\uff0c\u7279\u5225\u662f\u751f\u6210\u6a21\u578b\uff0c\u70ba\u9019\u4e9b\u6311\u6230\u63d0\u4f9b\u4e86\u6f5b\u5728\u7684\u89e3\u6c7a\u65b9\u6848\u3002\u4e00\u7a2e\u6709\u524d\u9014\u7684\u6f14\u7b97\u6cd5\u662f DrugGPT\uff0c\u9019\u662f\u4e00\u7a2e\u57fa\u65bc\u8f49\u63db\u5668\u7684\u6a21\u578b\uff0c\u5b83\u70ba\u8f38\u5165\u86cb\u767d\u8cea\u5e8f\u5217\u751f\u6210\u5c0f\u5206\u5b50\u3002\u5118\u7ba1\u6709\u524d\u666f\uff0c\u4f46\u5b83\u65e2\u7522\u751f\u5316\u5b78\u6709\u6548\u7d50\u69cb\uff0c\u4e5f\u7522\u751f\u7121\u6548\u7d50\u69cb\uff0c\u4e26\u4e14\u4e0d\u5305\u542b\u5df2\u6838\u51c6\u85e5\u7269\u7684\u7279\u5fb5\uff0c\u5c0e\u81f4\u8017\u6642\u4e14\u4f4e\u6548\u7684\u85e5\u7269\u767c\u73fe\u3002\u70ba\u4e86\u89e3\u6c7a\u9019\u4e9b\u554f\u984c\uff0c\u6211\u5011\u5f15\u5165\u4e86 DrugGen\uff0c\u9019\u662f\u4e00\u7a2e\u57fa\u65bc DrugGPT \u7d50\u69cb\u7684\u589e\u5f37\u6a21\u578b\u3002DrugGen \u5728\u5df2\u6838\u51c6\u7684\u85e5\u7269\u76ee\u6a19\u4ea4\u4e92\u4f5c\u7528\u4e0a\u9032\u884c\u5fae\u8abf\uff0c\u4e26\u4f7f\u7528\u8fd1\u7aef\u7b56\u7565\u6700\u4f73\u5316\u9032\u884c\u6700\u4f73\u5316\u3002\u901a\u904e\u4f7f\u7528\u9810\u5148\u8a13\u7df4\u7684\u8f49\u63db\u5668 (PLAPT) \u548c\u81ea\u8a02\u7121\u6548\u7d50\u69cb\u8a55\u4f30\u5668\uff0c\u5f9e\u86cb\u767d\u8cea\u914d\u9ad4\u7d50\u5408\u89aa\u548c\u529b\u9810\u6e2c\u4e2d\u63d0\u4f9b\u734e\u52f5\u56de\u994b\uff0cDrugGen \u5927\u5e45\u63d0\u5347\u4e86\u6548\u80fd\u3002\u591a\u500b\u76ee\u6a19\u7684\u8a55\u4f30\u986f\u793a\uff0c\u8207 DrugGPT \u7684 95.5% \u76f8\u6bd4\uff0cDrugGen \u9054\u5230\u4e86 100% \u7684\u6709\u6548\u7d50\u69cb\u751f\u6210\uff0c\u4e26\u4e14\u7522\u751f\u4e86\u9810\u6e2c\u7d50\u5408\u89aa\u548c\u529b\u8f03\u9ad8\u7684\u5206\u5b50 (7.22 [6.30-8.07])\uff0c\u800c DrugGPT \u70ba (5.81 [4.97-6.63])\uff0c\u540c\u6642\u4fdd\u6301\u4e86\u591a\u6a23\u6027\u548c\u65b0\u7a4e\u6027\u3002\u5c0d\u63a5\u6a21\u64ec\u9032\u4e00\u6b65\u9a57\u8b49\u4e86\u5176\u6709\u6548\u751f\u6210\u5206\u5b50\u4ee5\u91dd\u5c0d\u7d50\u5408\u4f4d\u9ede\u7684\u80fd\u529b\u3002\u4f8b\u5982\uff0c\u5728\u8102\u80aa\u9178\u7d50\u5408\u86cb\u767d 5 (FABP5) \u7684\u60c5\u6cc1\u4e0b\uff0c\u8207\u53c3\u8003\u5206\u5b50\uff08\u68d5\u6ada\u9178\uff0c-6.177\uff09\u76f8\u6bd4\uff0cDrugGen \u751f\u6210\u4e86\u5c0d\u63a5\u8a55\u5206\u8f03\u9ad8\u7684\u5206\u5b50 (FABP5/11\uff0c-9.537 \u548c FABP5/5\uff0c-8.399)\u3002\u9664\u4e86\u5148\u5c0e\u5316\u5408\u7269\u751f\u6210\u4e4b\u5916\uff0cDrugGen \u9084\u986f\u793a\u4e86\u85e5\u7269\u91cd\u65b0\u5b9a\u4f4d\u548c\u70ba\u73fe\u6709\u76ee\u6a19\u5efa\u7acb\u65b0\u578b\u85e5\u6548\u5718\u7684\u6f5b\u529b\u3002\u901a\u904e\u7522\u751f\u9ad8\u54c1\u8cea\u7684\u5c0f\u5206\u5b50\uff0cDrugGen \u70ba\u63a8\u9032\u88fd\u85e5\u7814\u7a76\u548c\u85e5\u7269\u767c\u73fe\u63d0\u4f9b\u4e86\u4e00\u500b\u9ad8\u6027\u80fd\u7684\u5a92\u4ecb\u3002", "author": "Mahsa Sheikholeslami et.al.", "authors": "Mahsa Sheikholeslami, Navid Mazrouei, Yousof Gheisari, Afshin Fasihi, Matin Irajpour, Ali Motahharynia", "id": "2411.14157v1", "paper_url": "http://arxiv.org/abs/2411.14157v1", "repo": "https://huggingface.co/alimotahharynia/DrugGen"}}